MERIMEPODIB
|
|
|
- CAS號(hào):
- 198821-22-6
- 英文名:
- MeriMepodib, VI-21497, VX-497
- 英文別名:
- VI 21497;Merimepodib, 10 mM in DMSO;MeriMepodib, VI-21497, VX-497;MERIMEPODIB; VX497; VX-497; VX 497; MMP; VI21497; VI-21497; VI 21497;(S)-Tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate;HCV,Inhibitor,Merimepodib,HBV,Hepatitis C virus,Hepatitis B virus,VX497,VX 497,inhibit,MMPD;[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate;[[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic acid (3S)-tetrahydro-3-furanyl ester;Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester
- 中文名:
- MERIMEPODIB
- 中文別名:
- 美泊地布;美泊地布,10 MM DMSO 溶液;(S)-四氫呋喃-3-基 3-(3-(3-甲氧基-4-(惡唑-5-基)苯基)脲基)芐基氨基甲酸酯
- CBNumber:
- CB62680808
- 分子式:
- C23H24N4O6
- 分子量:
- 452.46
- MOL File:
- 198821-22-6.mol
|
|
|
MERIMEPODIB化學(xué)性質(zhì)
-
沸點(diǎn):
-
571.4±50.0 °C(Predicted)
-
|
-
密度:
-
1.36±0.1 g/cm3(Predicted)
-
|
-
儲(chǔ)存條件:
-
Sealed in dry,Room Temperature
-
|
-
溶解度:
-
≥45.2 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
-
|
-
形態(tài):
-
solid
-
|
-
酸度系數(shù)(pKa):
-
11.66±0.46(Predicted)
-
|
-
顏色:
-
Off-white to light yellow
-
|
MERIMEPODIB性質(zhì)、用途與生產(chǎn)工藝
Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) 是一種有效、特異性和可逆的inosine monophosphate dehydrogenase(IMPDH)抑制劑，在體外對(duì)丙型肝炎病毒(HCV)和多種DNA和RNA病毒具有抗病毒活性。Merimepodib是一種免疫抑制劑。
VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC
50
s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC
50
of 380 nM and a corresponding CC
50
of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine.
Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED
50
value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals.
MERIMEPODIB
上下游產(chǎn)品信息
上游原料
下游產(chǎn)品
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS編號(hào) | 包裝 | 價(jià)格 |
|---|
| 2025/02/05 | S6689 | MERIMEPODIB
Merimepodib | 198821-22-6 | 5mg | 1170.13元 |
| 2025/02/05 | S6689 | MERIMEPODIB
Merimepodib | 198821-22-6 | 25mg | 3350.54元 |
198821-22-6, MERIMEPODIB 相關(guān)搜索:
- 抑制劑
- 合成有機(jī)化合物配體
- 小分子
- 美泊地布,10 MM DMSO 溶液
- (S)-四氫呋喃-3-基 3-(3-(3-甲氧基-4-(惡唑-5-基)苯基)脲基)芐基氨基甲酸酯
- 美泊地布
- 198821-22-6
- Merimepodib, 10 mM in DMSO
- HCV,Inhibitor,Merimepodib,HBV,Hepatitis C virus,Hepatitis B virus,VX497,VX 497,inhibit,MMPD
- (S)-Tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate
- MERIMEPODIB; VX497; VX-497; VX 497; MMP; VI21497; VI-21497; VI 21497
- [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate
- Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester
- VI 21497
- [[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic acid (3S)-tetrahydro-3-furanyl ester
- MeriMepodib, VI-21497, VX-497